Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines

Ferlay, 2015, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int. J. Cancer, 136, E359, 10.1002/ijc.29210 El-Serag, 2003, The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update, Ann. Intern. Med., 139, 817, 10.7326/0003-4819-139-10-200311180-00009 Prorok, 1992, Epidemiologic approach for cancer screening: problems in design and analysis of trials, Am. J. Pediatr. Hematol. Oncol., 14, 117, 10.1097/00043426-199205000-00005 Kramer, 2009, Cancer screening: the clash of science and intuition, Annu. Rev. Med., 60, 125, 10.1146/annurev.med.60.101107.134802 Chen, 2003, Screening for liver cancer: results of a randomised controlled trial in Qidong, China, J. Med. Screen., 10, 204, 10.1258/096914103771773320 Zhang, 2004, Randomized controlled trial of screening for hepatocellular carcinoma, J. Cancer Res. Clin. Oncol., 130, 417, 10.1007/s00432-004-0552-0 Yeh, 2014, Evaluation of abdominal ultrasonography mass screening for hepatocellular carcinoma in Taiwan, Hepatology, 59, 1840, 10.1002/hep.26703 Singal, 2009, Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis, Aliment Pharmacol. Ther., 30, 37, 10.1111/j.1365-2036.2009.04014.x Poustchi, 2011, Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed?, Hepatology, 54, 1998, 10.1002/hep.24581 European Association for the Study of the Liver, 2012, EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma, J. Hepatol., 56, 908, 10.1016/j.jhep.2011.12.001 Bruix, 2011, Management of hepatocellular carcinoma: an update, Hepatology, 53, 1020, 10.1002/hep.24199 Bruix, 2005, Management of hepatocellular carcinoma, Hepatology, 42, 1208, 10.1002/hep.20933 Jepsen, 2012, Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish nationwide cohort study, Ann. Intern. Med., 156, 841, 10.7326/0003-4819-156-12-201206190-00004 Mancebo, 2013, Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups, Clin. Gastroenterol. Hepatol., 11, 95, 10.1016/j.cgh.2012.09.007 Nahon, 2009, Myeloperoxidase and superoxide dismutase 2 polymorphisms comodulate the risk of hepatocellular carcinoma and death in alcoholic cirrhosis, Hepatology, 50, 1484, 10.1002/hep.23187 Verslype, 2012, Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann. Oncol., 23, 41, 10.1093/annonc/mds225 Marrero, 2009, Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma, Gastroenterology, 137, 110, 10.1053/j.gastro.2009.04.005 Singal, 2012, Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis, Cancer Epidemiol. Biomark. Prev., 21, 793, 10.1158/1055-9965.EPI-11-1005 Pocha, 2013, Surveillance for hepatocellular cancer with ultrasonography vs: computed tomography – a randomised study, Aliment Pharmacol. Ther., 38, 303, 10.1111/apt.12370 Giorgio, 2016, Contrast-enhanced ultrasound: a simple and effective tool in defining a rapid diagnostic work-up for small nodules detected in cirrhotic patients during surveillance, J. Gastrointest. Liver Dis., 25, 205, 10.15403/jgld.2014.1121.252.chu Forner, 2015, Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules <2 cm, J. Hepatol., 62, 150, 10.1016/j.jhep.2014.08.028 Atiq, 2016, An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis, Hepatology Sutherland, 2016, Diffusion-weighted MRI for hepatocellular carcinoma screening in chronic liver disease: direct comparison with ultrasound screening, J. Med. Imaging Radiat. Oncol. Besa, 2016, Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid, Abdom. Radiol. (NY) Bizollon, 1998, Diagnostic value and tolerance of Lipiodol-computed tomography for the detection of small hepatocellular carcinoma: correlation with pathologic examination of explanted livers, J. Hepatol., 28, 491, 10.1016/S0168-8278(98)80324-3 Vilana, 2010, Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound, Hepatology, 51, 2020, 10.1002/hep.23600 Galassi, 2013, Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound, Liver Int., 33, 771, 10.1111/liv.12124 Huang, 2016, Small intrahepatic cholangiocarcinoma and hepatocellular carcinoma in cirrhotic livers may share similar enhancement patterns at multiphase dynamic MR imaging, Radiology, 281, 150, 10.1148/radiol.2016151205 Ciresa, 2015, Enhancement patterns of intrahepatic mass-forming cholangiocarcinoma at multiphasic computed tomography and magnetic resonance imaging and correlation with clinicopathologic features, Eur. Rev. Med. Pharmacol. Sci., 19, 2786 Bruix, 2016, Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma, Gastroenterology, 150, 835, 10.1053/j.gastro.2015.12.041 Kojiro, 2005, Early hepatocellular carcinoma and dysplastic nodules, Semin. Liver Dis., 25, 133, 10.1055/s-2005-871193 Forner, 2008, Diagnosis of hepatic nodules 20 mm or smallerin cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma, Hepatology, 47, 97, 10.1002/hep.21966 Sangiovanni, 2010, The diagnostic and economic impact of contrast imaging technique in the diagnosis of small hepatocellular carcinoma in cirrhosis, Gut, 59, 638, 10.1136/gut.2009.187286 Khalili, 2011, Optimization of imaging diagnosisof 1–2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization, J. Hepatol., 54, 723, 10.1016/j.jhep.2010.07.025 Torbenson, 2015, Liver cancer biopsy–back to the future?, Hepatology, 61, 431, 10.1002/hep.27545 Schirmacher, 2011, Fighting the bushfire in HCC trials, J. Hepatol., 55, 276, 10.1016/j.jhep.2011.03.004 Sherman, 2011, Biopsy for Liver Cancer: how to balance research needs with evidence-based clinical practice, Hepatology, 53, 1020 Mitchell, 2015, LI-RADS (Liver imaging reporting and data system): summary, discussion, consensus of the LI-RADS management working group and future directions, Hepatology, 61, 1056, 10.1002/hep.27304 Darnell, 2015, Liver imaging reporting and data system with MR imaging: evaluation in nodules 20 mm or smaller detected in cirrhosis at screening US, Radiology, 275, 698, 10.1148/radiol.15141132 Sirlin, 2014, Consensus report from the 6th international forum for liver MRI using gadoxetic acid, J. Magn. Reson. Imaging, 40, 516, 10.1002/jmri.24419 Hope, 2015, Hepatobiliary agents and their role in LI-RADS, Abdom. Imaging, 40, 613, 10.1007/s00261-014-0227-5 Neri, 2016, ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents, Eur. Radiol., 26, 921, 10.1007/s00330-015-3900-3 Gschwend, 2011, Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment, Invest. Radiol., 46, 556, 10.1097/RLI.0b013e31821a218a Okada, 2016, Biochemical and clinical predictive approach and time point analysis of hepatobiliary phase liver enhancement on Gd-EOB-DTPA–enhanced MR images: a multicenter study, Radiology, 281, 474, 10.1148/radiol.2016151061 Van Beers, 2012, Primovist, Eovist: what to expect?, J. Hepatol., 57, 421, 10.1016/j.jhep.2012.01.031 Kitao, 2011, The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging, Eur. Radiol., 21, 2056, 10.1007/s00330-011-2165-8 Joo, 2015, Noninvasive diagnosis of hepatocellular carcinoma on gadoxético acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout, Eur. Radiol., 25, 2859, 10.1007/s00330-015-3686-3 Yu, 2014, Small (≤1-cm) Hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid–enhanced MR imaging, Radiology, 271, 748, 10.1148/radiol.14131996 Sano, 2011, Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid–enhanced MR imaging, Radiology, 261, 834, 10.1148/radiol.11101840 Ichikawa, 2010, Invest. Radiol., 45, 133, 10.1097/RLI.0b013e3181caea5b Kim, 2011, Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: characterization with gadoxetic acid–enhanced MRI that includes diffusion-weighted imaging, AJR, 196, W758, 10.2214/AJR.10.4394 Granito, 2013, Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study, Aliment Pharmacol. Ther., 37, 355, 10.1111/apt.12166 Bartolozzi, 2013, Contrast-enhanced magnetic resonance imaging of 102 nodules in cirrhosis: correlation with histological findings on explanted livers, Abdom. Imaging, 38, 290, 10.1007/s00261-012-9952-9 Choi, 2013, Hepatocellular carcinoma: imaging patterns on gadoxetic acid–enhanced MR images and their value as an imaging biomarker, Radiology, 267, 776, 10.1148/radiol.13120775 Golfieri, 2012, Which is the best MRI marker of malignancy for atypical cirrhotic nodules: hypointensity in hepatobiliary phase alone or combined with other features? Classification after Gd-EOB-DTPA administration, J. Magn. Reson. Imaging, 36, 648, 10.1002/jmri.23685 Faletti, 2015, Multiparametric Gd-EOB-DTPA magnetic resonance in diagnosis of HCC: dynamic study, hepatobiliary phase, and diffusion weighted imaging compared to histology after orthotopic liver transplantation, Abdom. Imaging, 40, 46, 10.1007/s00261-014-0180-3 Golfieri, 2014, Focal lesions in the cirrhotic liver: their pivotal role in gadoxetic acid-enhanced MRI and recognition by the western guidelines, Dig. Dis., 32, 696, 10.1159/000368002 Choi, 2016, Diagnostic criteria for hepatocellular carcinoma 3 cm with hepatocyte-specific contrast-enhanced magnetic resonance imaging, Radiology, 64, 1099 Piana, 2011, New MR imaging criteria with a diffusion-weighted sequence for the diagnosis of hepatocellular carcinoma in chronic liver diseases, J. Hepatol., 55, 126, 10.1016/j.jhep.2010.10.023 Taouli, 2012, Diffusion-weighted MR imaging for liver lesion characterization: a critical look, Radiology, 262, 378, 10.1148/radiol.11112417 Bieze, 2014, Diagnostic accuracy of (18) F-methylcholine positron emissiontomography/computed tomography for intra- and extrahepatic hepatocellular carcinoma, Hepatology, 59, 996, 10.1002/hep.26781 Castilla-Lièvre, 2016, Diagnostic value of combining 11C-choline and 18F-FDG PET/CT in hepatocellular carcinoma, Eur. J. Nucl. Med. Mol. Imaging, 43, 852, 10.1007/s00259-015-3241-0 Llovet, 1999, Prognosis of hepatocellular carcinoma: the BCLC staging classifi cation, Semin. Liver Dis., 19, 329, 10.1055/s-2007-1007122 A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators, [No authors listed] Hepatology, 28 (September (3)) 1998:751–5. Bolondi, 2012, Het-erogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma:proposal for a subclassification to facilitate treatment decisions, Semin. Liver Dis., 32, 348 Yau, 2014, Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocelular carcinoma, Gastroenterology, 146, 1691, 10.1053/j.gastro.2014.02.032 Bruix, 2016, Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Ferrer-Fabrega, 2016, Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection, Hepatology, 63, 839, 10.1002/hep.28339 Forner, 2016, Diagnosis and treatment of hepatocelular carcinoma Update consensus from the AEEH, SEOM, SERAM, SERVEI and SETH, Med. Clin., 146, 511, 10.1016/j.medcli.2016.01.028 Renzulli, 2016, Can current preoperative imaging be used to detect microvascular invasion of hepatocellular carcinoma, Radiology, 279, 432, 10.1148/radiol.2015150998 Lei, 2016, Nomogram for preoperative estimation of microvascular invasión risk in hepatitis B virus-related hepatocellular carcinoma within the milan criteria, JAMA Surg., 151, 356, 10.1001/jamasurg.2015.4257